Chetomin induces degradation of XIAP and enhances TRAIL sensitivity in urogenital cancer cells

International Journal of Oncology

Volumn 38, Issue 2, 2011, Pages 365-374

  Yano, Kimihiro ^a   Horinaka, Mano ^a   Yoshida, Tatsushi ^a   Yasuda, Takashi ^a   Taniguchi, Hiroya ^a   Goda, Ahmed E ^a,b   Wakada, Miki ^a   Yoshikawa, Sae ^a   Nakamura, Terukazu ^a   Kawauchi, Akihiro ^a   Miki, Tsuneharu ^a   Sakai, Toshiyuki ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Tanta University   (Egypt)

Author keywords

Chetomin; TRAIL; Urogenital cancer; XIAP

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 10; CASPASE 3; CASPASE 8; CASPASE 9; CHETOMIN; PIPERAZINEDIONE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ARTICLE; BLADDER CANCER; CANCER CELL; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; KIDNEY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION;

APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL PROLIFERATION; DISULFIDES; DRUG SYNERGISM; HUMANS; INDOLE ALKALOIDS; KIDNEY NEOPLASMS; MALE; MYCOTOXINS; PROSTATIC NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 78651235220     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2010.874     Document Type: Article

References (42)

1. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004.
2. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon α in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124, 2007. (Pubitemid 46089672)
3. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134, 2007.
4. Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995.
5. Ashkenazi A, Pai RC, Fong S, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162, 1999.
6. Keane MM, Ettenberg SA, Nau MM, Russell EK and Lipkowitz S: Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59: 734-741, 1999.
7. Lawrence D, Shahrokh Z, Marsters S, et al: Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7: 383-385, 2001.
8. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271: 12687-12690, 1996. (Pubitemid 26175834)
9. Walczak H, Miller RE, Ariail K, et al: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163, 1999.
10. Ashkenazi A and Herbst RS: To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 118: 1979-1990, 2008.
11. Zhang L and Fang B: Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12: 228-237, 2005.
12. Schimmer AD, Dalili S, Batey RA and Riedl SJ: Targeting XIAP for the treatment of malignancy. Cell Death Differ 13:179-188, 2006.
13. Mizutani Y, Nakanishi H, Li YN, et al: Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int J Oncol 30: 919-925, 2007.
14. Li M, Song T, Yin ZF and Na YQ: XIAP as a prognostic marker of early recurrence of nonmuscular invasive bladder cancer. Chin Med J 120: 469-473, 2007.
15. Seligson DB, Hongo F, Huerta-Yepez S, et al: Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence. Clin Cancer Res 15: 6056-6063, 2007.
16. Ndozangue-Touriguine O, Sebbagh M, Merino D, Micheau O, Bertoglio J and Breard J: A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma. Oncogene 27: 6012-6022, 2008.
17. Wilkinson JC, Cepero E, Boise LH and Duckett CS: Upstream regulatory role for XIAP in receptor-mediated apoptosis. Mol Cell Biol 24: 7003-7014, 2004.
18. Deveraux QL, Roy N, Stennicke HR, et al: IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 17: 2215-2223, 1998.
19. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ and Borden EC: Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/ TRAIL-induced apoptosis. Cell Death Differ 11: 915-923, 2004.
20. McManus DC, Lefebvre CA, Cherton-Horvat G, et al: Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene 23: 8105-8117, 2004.
21. Kung AL, Zabludoff SD, France DS, et al: Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6: 33-43, 2004.
22. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M and Sakai T: Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23: 6261-6271, 2004.
23. Zu K, Bihani T, Lin A, Park YM, Mori K and Ip C: Enhanced selenium effect on growth arrest by BiP/GRP78 knockdown in p53-null human prostate cancer cells. Oncogene 25: 546-554, 2006.
24. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG and Earnshaw WC: Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371: 346-347, 1994.
25. Yang Y, Fang S, Jensen JP, Weissman AM and Ashwell JD: Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 288: 874-877, 2000.
26. Dan HC, Sun M, Kaneko S, et al: Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 279: 5405-5412, 2004.
27. Goda AE, Yoshida T, Horinaka M, et al: Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Oncogene 29: 3435-3445, 2008.
28. Taniguchi H, Yoshida T, Horinaka M, et al: Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells. Cancer Res 68: 8918-8927, 2008.
29. Yasuda T, Yoshida T, Goda AE, et al: Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with TRAIL. Mol Cancer Res 6: 1852-1860, 2008.
30. Schimmer AD, Welsh K, Pinilla C, et al: Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5: 25-35, 2004.
31. Cillessen SA, Reed JC, Welsh K, et al: Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells. Blood 1: 369-375, 2008.
32. Kitada S, Zapata JM, Andreeff M and Reed JC: Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine downregulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 96: 393-397, 2000.
33. Rosato RR, Dai Y, Almenara JA, Maggio SC and Grant S: Potent antileukemic interactions between flavopiridol and TRAIL/ Apo2L involve flavopiridol- mediated XIAP downregulation. Leukemia 18: 1780-1788, 2004.
34. Carter BZ, Mak DH, Schober WD, et al: Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood 108: 630-637, 2006.
35. Carter BZ, Mak DH, Schober WD, et al: Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood 111: 3742-3750, 2008.
36. Makhov P, Golovine K, Uzzo RG, et al: Zinc chelation induces rapid depletion of the X-linked inhibitor of apoptosis and sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Cell Death Differ 15: 1745-1751, 2008.
37. Vogler M, Walczak H, Stadel D, et al: Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 69: 2425-2434, 2009.
38. Thayaparasingham B, Kunz A, Peters N and Kulms D: Sensitization of melanoma cells to TRAIL by UVB-induced and NF-κB-mediated downregulation of xIAP. Oncogene 28: 345-362, 2009.
39. Eckelman BP, Salvesen GS and Scott FL: Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 7: 988-994, 2006.
40. Sasaki H, Sheng Y, Kotsuji F and Tsang BK: Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 60: 5659-5666, 2000.
41. Hu Y, Cherton-Horvat G, Dragowska V, et al: Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 9: 2826-2836, 2003.
42. LaCasse EC, Cherton-Horvat GG, Hewitt KE, et al: Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res 12: 5231-5241, 2006.